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Human heart failure is a major health and economic burden. Recent
evidence suggests that the adult myocardium may be able to generate
some new cardiac myocytes after injury; however, this is insufﬁcient to
lead to meaningful functional recovery [1,2]. Furthermore, the paucity
of organs for transplantation limits curative approaches for the diseased
adult heart. As an alternative approach, stem cell-based therapies have
been investigated for their capacity to repair the damaged heart. For ex-
ample, non-cardiac cells obtained frombonemarrow-derivedmesenchy-
mal stem cells (MSCs) have been studiedwith limited success [3,4]. More
recently, human induced pluripotent stem cell-derived cardiac myocytes
(hiPSC-CMs) have been gaining attention as a potentially viable alterna-
tive. While exciting in principle, hiPSC-CMs do have several hurdles to
overcome before meaningful translational lab-to-clinic advances can be
made. It is generally viewed that hiPSC-CMs are immature as they do
not display the requisite sub-cellular, cellular and tissue-level adult
myocyte morphology and sarcomeric protein content and organization
[5–7]. Maturation of hiPSC-CMs is indispensable because it underlies
the required physiological functions of the cell, including intracellularyocyte Biology: Integration of
edited by Marcus Schaub and
Biology & Physiology, Medical
Church Street SE, Minneapolis,
. This is an open access article underCa2+ handling, contractile force, and relaxation [8,9]. In order to realize
the potential applications of mature hiPSC-CMs to the emerging ﬁeld of
personalized medicine, as well as for disease modeling and drug discov-
ery, further testing and reﬁnement are paramount.
2. Focus and rationale
Although efﬁcient cardiac myocytes can be generated from hiPSCs
after differentiation using small molecules [7] (Fig. 1), directing these
cells to acquire the physiological structure, gene expression proﬁle,
and function akin to mature cardiac tissue remains a major obstacle.
This reviewwill focus on the developmental progression of fetal cardiac
myocytes (maturation), growth and nuclear kinetics (ploidy), and gene
expression, with emphasis on disease-unaltered isoforms, such as TnI
isoforms and chamber speciﬁc isoforms, as well as disease-altered iso-
forms. Finally, factors that promote maturation of hiPSC-CMs will be
reviewed together with an assessment of efforts to characterize the
functional properties of hiPSC-CMs, culminating in a discussion of
practical applications of hiPSC-CMs.
3. Developmental progression of fetal cardiac myocytes
Fetal cardiac myocytes are characterized by amorphous cell
morphology, nascent sarcomere formation, embryonic/fetal gene ex-
pression, rudimentary Ca2+ cycling, and spontaneous beating (Fig. 2)
[7,10,11]. As development progresses, enhanced sarcomere formation
ensues with expression of developmental and chamber-speciﬁc sarco-
meric isoforms, reﬁned Ca2+ cycling, and synchronized beating [7,10,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Differentiation of hiPSC-CMs. Schematic of the differentiation protocol for hiPSC-
CMs as described recently [7,13].
1830 F.B. Bedada et al. / Biochimica et Biophysica Acta 1863 (2016) 1829–183811]. Further developmental maturation results in typical rod-shaped
morphology with deﬁned sarcomeres and, importantly, key signatures
of adult isoform expression, such as expression of cTnI, which confers
robustmechanical performance, as well as expression of the ventricular
marker MLC2v [12,13]. Interestingly, during cardiac disease the adult
myocardium resorts to expression of a fetal sarcomeric gene program
by up-regulation of key fetal isoforms [7]. In this review we assess
hiPSC-CMmaturation in the context of the fetal-to-adult developmental
transition obtained during normal heart development.4. Physiological growth and nuclear kinetics
The proliferation of cardiac myocytes is the major factor for the in-
crease in the size of the heart during development [14]. The increasing
circulatory demand of the developing embryo is matched with an in-
crease in heart mass via cell proliferation. Ultimately, cardiac myocyte
turnover, in concert with cell migration and programmed cell death, is
an essential element in the developing heart [14]. Although fetal hearts
from both humans and rodents grow through the proliferation of
mono-nucleated cardiac myocytes with diploid nuclei, variation exists
in the timing of cell cyclewithdrawal [15]. Rodent cardiacmyocyteswith-
draw from the cell cycle shortly after birth, but human cardiac myocytes
continue to proliferate for severalmonths after birth, although this prolif-
eration slows with time [15,16]. This complete cell division process,
where karyokinesis is coupled with cytokinesis, is evident in rodent and
human myocytes as they undergo a period of physiological growth (hy-
pertrophy) to increase overall heart mass [11,15]. This physiological
growth is different from pathological hypertrophic growth, whereFig. 2.Developmental progression of cardiacmyocytes. The pyramid depicts the developmental
of the fetal program during heart disease.postnatal human and rodent cardiac myocytes exhibit different nuclear
kinetics. For example, in rodents, more than 75% of cardiac myocytes
are bi-nucleated [11,15]. This bi-nucleation occurs via incomplete cell di-
visions that involve DNA replication and nuclear division without
cytokinesis (acytokinetic mitosis) with each nucleus having normal dip-
loid (2n) DNA content [15–17]. In comparison, most adult cardiac
myocytes are mono-nucleated and tetraploid in humans and primates
[11,15,18]. Human cardiac myocytes attain mono-nucleation and poly-
ploidy by undergoing DNA replicationwithout nuclear division or cytoki-
nesis, [15,18], culminating in tetraploidy (4n) or polyploidy [15,19].
Olivetti et al. demonstrated that the proportion of mono-nucleated
human cardiac myocytes in the adult heart is 74% and that of bi-
nucleated cardiacmyocytes is 25.5% [18]. Paralleling the increase ofmyo-
cardial mass, the percentage of diploid cardiac myocyte nuclei decreases
in the human heart [15]. Polyploidization occurs in the pre-adolescent
growth phase with tetraploid nuclei (4n) being themost common ploidy
state in the adult human heart [11,15]. Collectively, bi-nucleation (DNA
replication with karyokinesis but without cytokinesis) in postnatal ro-
dentmyocytes and polyploidization (DNA replicationwithout karyokine-
sis or cytokinesis) in postnatal human myocytes are examples of
incomplete cell division or nonproductive cell cycling that do not neces-
sarily contribute to cardiac myocyte turnover or new cardiac myocyte
formation. This is a hallmark of the postnatal mammalian heart [15].5. Markers of maturation
Quantitative methods to track hiPSC-CM maturation are critically
important and currently limited. One of the great challenges of an effec-
tivematurationmarker rests in its “reliability” as an adult marker.Many
potential cardiac markers of the adult mature state are susceptible to
change in that they can “revert” to a fetal signature during stress, thus
compromising their function as an adult marker. Recently, we have
demonstrated the usefulness of troponin I isoforms as a valid quantita-
tive marker of maturation that overcomes this key limitation [7]. The
TnI isoforms are part of the thin-ﬁlament protein network and are
central to cardiac muscle function. In striated muscle, there are three
isoforms that are transcribed from three separate genes in a muscle-
ﬁber type-speciﬁc manner [20–22]. These isoforms are fast skeletaltransition from fetal stages to fullymature rod-shaped adultmyocytes, and the recurrence
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skeletal troponin I (ssTnI/TNNI1), expressed in slow skeletal muscle ﬁ-
bers and fetal cardiac muscle; and cardiac troponin I (cTnI/TNNI3),
expressed only in adult cardiac muscle. In this review, we focus on
ssTnI and cTnI because these two key myoﬁlament isoform proteins
are antithetically expressed during the transition from fetal to adult
life [22,23]. The ssTnI isoform is expressed during neonatal or fetal life
and is then stoichiometrically replaced by the cTnI isoform, which is ex-
clusively expressed in mature adult cardiac myocytes [22–27]. The cTnI
isoform has a unique N-terminal extension containing serine residues
that are phosphorylated in response to adrenergic stimulation of the
heart, making it PKA-responsive. This PKA responsiveness is critically
required for the fast relaxation that is necessary for optimal adult cardi-
ac function [28–30]. Thus, acquisition of this key adult signature matu-
ration marker by hiPSC-CMs is indispensable.
The unique advantage of this isoform switch as a quantitative mark-
er of maturation is that this isoform transition is not altered by disease
conditions such as hypertrophy or heart failure [23,24,31]. This is
distinct from other studied genes and isoforms that have been used as
markers of maturation in prior studies [32,33]. The transition of TnI iso-
forms during development has been understudied in addressing stem
cell-derived cardiac maturation. Currently, it is not entirely clear what
factors regulate the transition from ssTnI to cTnI. To address this, our re-
cent work evaluated developmental progression of hiPSC-CMs and
rodent-CMs after culturing in a de-cellularized cardiac matrix [7]. Re-
sults show matrix-induced cell alignment and sarcomere organization
of hiPSC-CMs (Fig. 3). Assessment of a mature signature, such as the
switch from ssTnI to cTnI, showed stalled developmental maturation
of hiPSC-CMs, with cTnI accounting for only 2% of all TnI expression
after 9.5 months in culture [7]. Although hiPSC-CMs expressed detect-
able cTnI after 2 months in culture, this did not increase after 6 to 9.5
months in culture. On the whole, the acquisition of a mature phenotype
for hiPSC-CMs in terms of the cTnI:ssTnI isoform ratio is extremely de-
layed compared to the developmental acquisition in rodent pups or in
cultured rodent CMs [7]. In order to use hiPSC-CMs for diseasemodeling
or drug studies, it is important to investigate this delayed maturation of
hiPSC-CMs. To this end, it is critical to incorporate the transition from
the ssTnI to the cTnI isoform, along with other key markers such as
MLC2v, as a readout of developmental progression.
6. Chamber speciﬁc isoforms in hiPSC-CMs
Cardiac myosin consists of two cardiac myosin light chain 2 (MLC2)
isoforms, MLC2a and MLC2v. In the developing human and mouseFig. 3. Structural organization of hiPSC-CMs. Schematic of hiPSC-CMs repopulating a biological
cultured in the absence of biological matrix (left panel). Calibration bar is 50 μm.heart, MLC2a expression is detected in all chambers [34]. In the postna-
tal heart, MLC2v is conﬁned to the ventricle, and this chamber speciﬁc-
ity persists to adulthood [34,35]. MLC2v expression is also considered to
be a marker of cardiac myocyte maturity [34,35]. Thus, we and others
have used the expression patterns of MLC2a andMLC2v to deﬁne cardi-
ac myocyte identity and stages of development. Recently, we reported
that hiPSC-CMs primarily express MLC2a at early time points. At later
time points, expression of MLC2v increases and expression of MLC2a
decreases, with the majority of hiPSC-CMs co-expressing both MLC2a
and MLC2v [7]. Here, hiPSC-CMs expressing MLC2v most likely repre-
sent ventricular-like cells, while those expressingMLC2amay represent
a range of immature cardiac myocytes, including atrial-like cells. Earlier
reports demonstrated prevalent MLC2v/MLC2a double-positive cardiac
myocytes, with disorganized sarcomeres and weak hERG channel re-
sponses, to be immature, resembling human fetal cardiac myocytes
[36]. The ultimate goal is to one day produce ventricular hiPSC-CMs
that fully express cTnI and MLC2v, and that have zero ssTnI expression,
as in adult myocardium.
7. Stress-altered markers of maturation
A large number of cardiac isoforms encoding different contractile
proteins exist in the sarcomere. Many genes that encode for contractile
proteins have a characteristic pattern of expression during develop-
ment, and many of these are also altered by disease conditions [37].
The failing heart reactivates fetal genes and reverts to a fetal pattern of
energy substrate metabolism [37,38]. For instance, levels of fetal genes
such as ANP, BNP, βMHC, skeletal actin, and metabolic genes such as
GLUT1 are reactivated in the failing adult heart [32,37,38]. Moreover,
αMHC, SERCA2a, ion channels, and metabolic genes such as GLUT4
are reduced during heart failure [32,39]. Because the failing adult
heart reverts to a fetal-like structural, hormonal and metabolic gene
proﬁle by down-regulating adult gene transcripts, the utility of these re-
versible markers, that are prone to changes during disease and culture
conditions, has to be interpretedwith caution. Thus, we recommend in-
corporation of isoforms that are not prone to such alteration, such as
ssTnI and cTnI, andMLC2a andMLC2v [23,24,40], into studies involving
hiPSC-CM maturation.
8. Structural maturation of hiPSC-CMs on a biological matrix
Sarcomerematuration in hiPSC-CMs is indispensable for the study of
disease modeling. Sarcomere structure maturation in cardiac myocytes
derived from human pluripotent stem cells could be achieved by cuesmatrix aligned and displaying sarcomere organization (right panel) compared with those
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shown that hiPSC-CMs and rodent CMs repopulated into a biological
cardiac matrix display sarcomere organization, as revealed by α-
actinin at the Z-line [7]. In contrast, the myoﬁbrils in these cell types
are oriented in multiple directions within the myocytes in the absence
of such a biological matrix (Fig. 3).
9. Molecular maturation of hiPSC-CMs with thyroid hormone (T3)
The role of T3 in regulating cardiac genes and isoforms iswell known
[42,43]. Studies have shown an increase in the expression of mRNA for
αMHC, cardiac actin, skeletal actin and calcium handling genes such as
SERCA2a following T3 treatment, suggesting an important role of T3 in
the regulation of cardiac genes [42,43]. Previous work demonstrated
that changes inmyosin heavy chain (MHC) isoforms that occur in failing
human hearts resemble the pattern produced in rodent myocardium in
response to hypothyroidism. Furthermore, failing or hypertrophied
human myocardium may have a defect in thyroid hormone signaling
due to alterations in expression of thyroid hormone receptors (TRs)
[38]. Recent work notwithstanding [44], our work has shown that
hiPSC-CMs do not respond to T3 treatment, despite the fact that rodent
CMs respond readily to T3 treatment [7].
10. Directed maturation of hiPSC-CMs with stoichiometric
replacement of TnI
Adult cardiac muscles are highly organized contractile machines.
Because the cardiacmyoﬁlament proteins are undergoing dynamic pro-
tein synthesis and turnover, stringent stoichiometry is required for the
assembly of myoﬁlament proteins. For instance, postnatal expression
of ssTnI is signiﬁcantly prolonged in the hearts of cTnI knockout (cTnI-
KO) mice [45], suggesting that cTnI accelerates ssTnI isoform turnover.
Because of the apparent developmental block in the acquisition of the
mature molecular signature marker (cTnI) in hiPSC-CMs, we sought to
complement hiPSC-CMs with exogenous adenoviral mediated gene
transfer of human cTnI. Stoichiometric gene replacement with exoge-
nous human cTnI signiﬁcantly and stoichiometrically increases cTnI
and reduces content of ssTnI in hiPSC-CMs [7]. The developmentally
stalled acquisition of a mature signature in hiPSC-CMs could thus be
accelerated with gene transfer of cTnI.
11. Functional characterization
Many researchers have devoted substantial effort to characterizing
pluripotent stem cell-derived cardiac myocytes in terms of gene and
protein expression. Over the course of differentiation, the cells are
thought to act much like early embryonic pluripotent and precursor
cells [46]. Here, the transition from pluripotency through mesodermal
and cardiac progenitor-like cells, culminating in a cardiacmyocyte phe-
notype over the course of 7–10 days, can be easily tracked through gene
proﬁle studies. Gene and protein expression proﬁles also allow charac-
terization of changes in differentiated cells, including limited phenotyp-
ic maturation, and isoform switching of adrenergic receptors, ion
channels, and sarcomeric proteins, as reviewed above. However, as a
myocyte's usefulness inherently depends onmore than simply gene ex-
pression, it is crucial to evaluate pluripotent stem cell-derived cardiac
myocytes in terms of properties necessary for functionality of a
contracting cell. These include electrical conductance, Ca2+ handling,
and contractility.
12. Electrical function
Due to the essential role of ionic currents and electrical conduction
in the functionality of cardiac muscle, deciphering electrical function
of iPSC-CMs allows researchers to characterize mature versus imma-
ture, healthy versus diseased cells, and ventricular versus atrial celltypes. However, at such an immature state, the last categorization
may be difﬁcult to distinguish, and attempting to do somay not provide
realistically useful information [47]. Generally, electrical function is
measured using extracellular ﬁeld potential recordings, sharp electrode
recordings, or patch clamp recordings.
Perhaps the easiest electrical assay to perform is the recording of
extracellular ﬁeld potentials using a multielectrode array (MEA). MEA
recording does not require recording from a single cell, but rather mea-
sures the voltage from a population of cells in a dish [48]. In cardiac
myocytes, the ﬁeld potential duration (FPD) corresponds to the action
potential duration (APD) of a single cell, which in turn corresponds to
the QT interval on the electrocardiogram, an important parameter for
researchers using iPSC-CMs to model arrhythmic diseases or as a
platform for drug discovery. This technique has been well validated in
hESC-CM models [48–50]. It has recently been further validated in
iPSC-CMs, demonstrating that it can be used to reliably detect drug-
induced arrhythmias and repolarization delay, even across distinct
facilities [51]. Recent work characterized and optimized ﬁeld potential
recordings, including in response to a drug, and included some limita-
tions of the method that should be taken into consideration when
performing experiments and data analysis [52].
In order to dissect out the role of speciﬁc currents and ions, single
cell electrophysiology techniques are useful, including patch clamp
and sharp electrode recording. A patch-clamp pipette can be attached
to the cell in several conﬁgurations, including cell-attached, whole-
cell, and perforated-patch modes. Patch clamp has been used to evalu-
ate currents in hiPSC-CMsderived frompatientswith longQT syndrome
type 2. This technique was employed to examine the effects of various
drugs on those cells, demonstrating its value in studying models of ar-
rhythmia [53]. Patch clamp electrophysiology has also been used to
evaluate individual currents of iPSC-CMs, including INa, ICa, IKr, and IKs,
as well as their ability to be blocked by known channel blockers [54].
It was concluded that use of iPSC-CMs for electrophysiology studies is
feasible. Similar experiments using an automated patch clamp technol-
ogy came to similar conclusions [55]. However, a separate group, using
patch clamp to study APD, AP frequency, AP shape, INa, and ICa, as well
as effects of channel blockers TTX and lidocaine, noted signiﬁcant vari-
ability between cells from different sources, and suggest utilizing
these techniques with caution [56].
Sharp electrode electrophysiology has been used in several pub-
lished iPSC-CM studies. Intracellular recordings of APs of murine iPSC-
CMs [57] and human iPSC-CMs [58] have been made to examine
whether the cells differentiated into atrial, ventricular, or nodal types.
However, due to the immature nature of these cells, cell types can be
difﬁcult to distinguish based on AP shape alone, and caution should be
usedwhen drawing conclusions from these types of experiments. Over-
all, these studies show that iPSC-CMs express appropriate ion channels
and have electrical activity similar to human cardiac myocytes, and can
be reliably tested for action potential duration, ion currents, and drug
interactions if appropriate precautions are taken when drawing
conclusions.13. Ca2+ handling in hiPSC-CMs
The adult ventricular cardiac myocyte displays a well-deﬁned se-
quence of events with regard to Ca2+ cycling. Ca2+ inﬂux via L-type
Ca2+ channels serves as an initial trigger, initiating Ca2+ release from
the sarcoplasmic reticulum by activating Ryanodine receptor 2 (RyR2)
via a process called calcium-induced calcium release (CICR) [59,60].
Phosphorylation of these channels increases calcium ﬂux, increasing
contractility. In general, little is known about the excitation contraction
coupling (ECC) and Ca2+ handling properties of hiPSC-CMs. Gene ex-
pression and immunostaining studies showed that key Ca2+ handling
proteins are expressed in hiPSC-CMs [61]. Furthermore, hiPSC-CMs are
dependent on both trans-sarcolemmal Ca2+ entry via L-type Ca2+
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SERCA2a pump-based Ca2+ reuptake [61].
The majority of Ca2+ in the cytoplasm during systole is released
from and then taken back up into the sarcoplasmic reticulum (SR)
[62]. Release is triggered by depolarization of the cell membrane, and,
as such, is intricately connected to AP activity of the cell as well as sarco-
mere contraction. However, it can be uncoupled fromboth, and it is nec-
essary to measure Ca2+ activity separately. Calcium transients in
myocytes are typically measured using ﬂuorescent Ca2+-binding dyes
on a ﬂuorescent microscope [62]. Satin et al. laid the groundwork
using hESC-CMs [63]. They loaded cells with the dye Fluo-4 AM and re-
corded intracellular Ca2+ transients with a confocal microscope. Using
this technique, they observed both entire-cell AP-driven transients, as
well as localized SR Ca2+ release events (sparks). They then used
caffeine to mobilize Ca2+ release from the SR, as well as ryanodine to
inhibit release from the ryanodine receptor RyR. They were able to pro-
vide evidence that hESC-CMs have large stores of Ca2+ in the SR, a hall-
mark ofmature cardiacmyocytes.Moving to iPSC-CMs, several labs [64]
[61] have imaged Ca2+ transients and sparks in healthy cells by loading
them with ﬂuo-4 under a confocal microscope, and used caffeine to
probe SR stores. Fura-4F, a ratiometric calciumdye, has been used to ob-
serve the propagation of Ca2+ transients through iPSC-CMmonolayers,
while simultaneously measuring intracellular voltage with the voltage-
sensitive ﬂuorescent dye, di-8-ANEPPS [65].
Using hiPSC-CMs derived from patients with catecholaminergic
polymorphic ventricular tachycardia (CPVT), a genetic arrhythmic de-
fect, differences were shown in Ca2+ handling in diseased versus
healthy cells based on Fluo-4 ﬂuorescent imaging [66]. Furthermore,
they used voltage clamping to directly measure the L-type Ca2+ current
(ICa) and theNa+–Ca2+ exchanger (INCX). A combinedﬂuorescent Ca2+
imaging with voltage-clamped ICa measurement can also demonstrate
changes in how iPSC-CMs handle Ca2+ as they mature [67]. Recently,
Ca2+ handling characteristics across cells derived in different
laboratories have been compared [68], using the ratiometric Ca2+ dye
Fura-2 AM and recording transients while the cells were electrically
stimulated. Using caffeine, SR Ca2+ stores were estimated, and ICa
wasmeasured bywhole-cell patch clamp. Overall, therewere compara-
ble results between these laboratories. To summarize, iPSC-CMs have
functional Ca2+ stores, and release and reuptake Ca2+ via the SR, and
these events can be detected by Ca2+-sensitive ﬂuorescent dyes such
as a Fura or a Fluo derivative.
14. Contractility
The most important parameter of a myocyte's function is its force
production, as this determines how effectively the organ can circulate
blood. An adult myocyte, with its well-organized sarcomeres and rect-
angular shape, can relatively easily be studied using video microscopy
or force transducers [69]. In comparison, the morphology of a stem
cell-derived myocyte presents some distinct challenges. Early on,
groups used video edge detection to track movement of stimulated
beating EBs as a percent of baseline length [70]. They were able to
show increased contractility in response to β-adrenergic stimulation, a
hallmark feature of cardiacmyocytes. HiPSC-CMsderived by amonolay-
er method can also be monitored by videomicroscopy. Motion tracking
software can be used to assess beating frequency, amplitude, and kinet-
ics of a 3D tissue-like construct formed by seeding iPSC-CMs onto a ﬁl-
amentous polymer matrix [71].
While video-based edge detection of contractility is highly useful,
the ability to measure force production against a load provides a more
direct measure of myocyte function. One approach to measuring force
involves seeding beating clusters from iPSC-derived EBs onto 300 μm-
thin strips of neonatal murine ventricular myocardium, and then
attaching the myocardial strip to force transducers for measurement
[57]. Sun et al., used single cell-dispersed iPSC-CMs derived from a pa-
tient with dilated cardiomyopathy to assess single-cell force productionusing atomic force microscopy. This approach relies on the microscope
for detecting changes in force at the cell surface caused by changes in
stiffnesswithin the cell, presumably due to rearrangement of sarcomer-
ic and cytoskeletal proteins during contraction [72]. However, it should
be noted that this is a technique that has not yet been validated in plu-
ripotent cell-derived cardiac myocytes, neonatal cardiac myocytes, or
adult myocytes. In the paper, the authors cite a paper exploring use of
the technique on embryonic chicken cardiac myocytes, where the au-
thors note that parameters such as beat period and pulse amplitude
were observed to be unstable [73].
The micropost array, a technique that has been well validated in
other myocyte cell types, has been used to measure contractile force
of iPSC-CMs [74]. In this assay, an array of microposts is fabricated
from polydimethylsiloxane (PDMS) using photolithography and the
tops of the posts are coated with ECM proteins, and cells are seeded
on top of that. As cells contract, the posts deﬂect with the cell, and
video microscopy with subsequent analysis is able to convert move-
ment into force needed to move the microposts. The authors were
able to examine different force production of cells that had been seeded
on different types of ECMprotein. In a similar vein, Sheehy et al. utilized
themuscular thinﬁlm (MTF) assay,wherein thin strips of PDMS are fab-
ricated and coated with ECM proteins. The iPSC-CMs are then seeded
and stimulated [75]. As cells contract, the MTFs bend and curvature is
analyzed with video microscopy, and force production is extrapolated
from MTF displacement. These studies show that iPSC-CMs produce a
force that is able to be measured; however, the techniques for force
measurement are not well developed, and there is an urgent need for
improved methods.
15. Applications
The technologies allowing dedifferentiation of cells into a pluripo-
tent state, and subsequent differentiation to cardiac phenotypes, have
been adopted by laboratories and research groups around the world
with remarkable speed. The study of iPSC-CMs has become its own
ﬁeld of research over the span of a few short years, and new discoveries
are made at a steady and impressive pace. An explanation for this rapid
pace of discovery lies in the wealth of potential uses and applications
envisioned for these cells (Fig. 4).
16. Disease models
Pluripotent stem cells derived from individualswith genetic diseases
can be used to illuminate disease phenotypes in an in vitromodel. Here,
iPSC-CMs derived from patients with known genetic mutations, espe-
cially monogenic mutations, that lead to cardiac phenotypes can be
used to probe gene function and potential therapies. With the electrical
assays readily available as mentioned above, an early target for disease
modeling with iPSC-CMs was Long QT syndrome, a genetic disorder
characterized by delayed repolarization of cardiac myocytes, a disease
that places patients at risk of deadly arrhythmias including Torsade de
Pointes and ventricular ﬁbrillation [76]. In hiPSC-CMs from patients
with Long QT Syndrome Type 3 (LQTS-3) (caused by mutations in the
sodium channel SCN5A) there is faster recovery from inactivation of
Na+ current in mutant cells versus wild-type cells, and a larger tetrodo-
toxin (TTX)-sensitive current in the mutant cells [76]. Both of these
ﬁndings are consistent with data from adult mouse myocyte studies
[77]. The group also found prolonged AP duration in SCN5A mutant
cells. Similar observations were made using iPSC-CMs from LQTS-3 pa-
tients, however with different mutations in the SCN5A gene [78]. Using
patch clamp to study Na+ and Ca2+ currents, as well as whole-cell cur-
rent clamp to measure AP, they found that LQTS cells have tendencies
toward prolonged AP duration, smaller Na+ current density, slower
time to inactivation, and increased time to peak.
At least three groups have studied LQTS using pluripotent cells from
patients with LQTS Type 2, caused by mutations in KCNH2 (hERG
Fig. 4.Overviewof experimental ﬂowutilizing hiPSC-CMs. Functionality of hiPSCs, having been differentiated into cardiac myocytes, is characterized in terms of electrical activity, calcium
cycling, and contractility. Fully characterized hiPSC-CMs are used for diverse applications including disease modeling, drug discovery, and therapeutic applications.
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group, using cells from a single patient, utilized whole-cell patch clamp
and found AP duration prolongation and reduced amplitude of peak IKr
activation and tail currents [79]. Using MEA, they reported prolonged
ﬁeld potential duration (FPD). Importantly, by looking at single cell AP
as well as MEA, they found signiﬁcant arrhythmogenicity in the form
of EADs and ectopic activity. The second [53] and third groups [80]
found similar prolongation of APD and FPD in KCNH2 mutant iPSC-
CMs. Furthermore, these studies demonstrated signiﬁcant reduction in
IKr density and enhanced arrhythmogenic potential. In hiPSC-CMs
from a patient with Timothy syndrome [caused by a mutation in the
L-type Ca2+ channel (CaV1.2)] the QT interval was prolonged [81]. This
study reported prolonged APD, arrhythmic activity, and abnormal
Ca2+ transients in the patient-derived cells compared to control cells.
Other models of arrhythmia have been studied using patient-derived
cells. Catecholaminergic polymorphic ventricular tachycardia (CPVT),
caused by amutation in the ryanodine receptor (RYR2), is characterized
by aberrant Ca2+ release from the SR and ventricular arrhythmia. Cells
derived from patients with this disease indeed show elevated diastolic
Ca2+ concentrations, reduced SR Ca2+ content, and susceptibility to
DAD in patient derived cells compared to control [82].Apart from arrhythmic disease models, other hereditary conditions
have been studied in patient-derived iPSC-CMs. Using cells derived
from a patient with Barth Syndrome, a mitochondrial disorder, it was
observed that the cells closely recapitulated several hallmarks of the
disease, including irregular sarcomere formation, irregular mitochon-
dria, and weak contractility [83]. Furthermore, they were able to eluci-
date mechanisms of pathophysiology of the disease involving excess
reactive oxygen species. Others have studied cells from a patient with
Pompe disease, a glycogen storage disorder caused by mutations in
acid alpha-glucosidase (GAA) [84]. Here the patient-derived hiPSC-
CMs showed abnormally high levels of glycogen andmitochondrial dys-
function, and ultrastructural abnormalities, consistent with ﬁndings
frommyocytes. In LEOPARD syndrome, a developmental disorder char-
acterized by a cluster of abnormal ﬁndings caused by mutations in the
Ras-MAPK signaling genes, a common abnormality is hypertrophic car-
diomyopathy. Differentiated iPSC-CMs derived from patients with a
mutation in a protein tyrosine phosphatase encoded by PTPN11, display
abnormal Ras-MAPK signaling, cell hypertrophy and abnormal sarco-
mere organization [85].
Models of cardiomyopathies, whilemore difﬁcult to study due to the
immature phenotype of iPSC-CMs, have also shown some progress. For
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ventricular cardiomyopathy (ARVC), a poorly-characterized disease as-
sociated with arrhythmia and sudden cardiac death, as well as ﬁbrofatty
replacement of the right ventricular myocardium [86]. This patient had a
mutation in PKP2, encoding plakophilin 2, a desmosomal protein. The
hiPSC-CMs from this patient showed decreased expression of desmo-
somal proteins and high levels of lipid storage. A separate in vitro
model of dilated cardiomyopathy (DCM) [72], characterized by eccentric
ventricular hypertrophy, decreased Ca2+ sensitivity, and impaired force
production, was derived from iPSCs from patients carrying a mutation
in cardiac troponin T (TNNT2) and their unaffected familymembers.Mu-
tant iPSC-CMs showed comparable cell size to control, but had deranged
sarcomere organization. They also had smaller Ca2+ transient ampli-
tudes and smaller SR Ca2+ stores, and lower force production based on
an atomic force microscopy assay. Overall, the immaturity of the iPSC-
CMs makes more challenging the ability to fully assess a disease
phenotype normally associated with mature myocytes.
A recent area of great research interest involves the use of genome
editing techniques. These include such technologies as transcription
activator-like effector nucleases (TALENs) and CRISPR/Cas9. Both cleave
DNA in a site-speciﬁc manner, which may be repaired by non-
homologous end-joining (NHEJ), potentially disrupting the gene, or, if a
template is provided, by homology-directed repair (HDR) [87]. These
can be used to introduce disease-speciﬁc mutations into an otherwise
healthy cell line, reducing noise from genetic variability between lines.
It may also be used to correct disease-causing mutations. Hematopoietic
diseases such as Fanconi Anemia, β-thalassemia, and myelodysplastic
syndrome have been modeled and corrected [88], but the technology
has not yet been extensively applied to cardiovascular disease.
Together, these studies demonstrate the feasibility and wide-
reaching capacity formodeling genetic diseases using iPSC-CMs. Emerg-
ing and advancing technologies will allow this capacity to increase even
further, and signiﬁcant advancesmay come from these studies thatmay
not be found in rodent and animal models.
17. Drug discovery
HiPSC-CMs express ion channels, including sodium channels, potas-
sium channels, the hERG (Kv1.1) channel, and the hyperpolarization-
activated cyclic nucleotide-gated (HCN) channel (funny current), that
have the potential to interact with many pharmaceutical compounds
[46]. Pharmaceutical researchers have a strong interest in identifying in-
teractions between these channels and potential clinical drugs due to
the severe risks that such interactions entail. As such, iPSC-CMs present
an attractive alternative for other models, such as isolated adult
myocytes, or human embryonic kidney cells or Chinese hamster ovary
cells that have been used to force expression of hERG channels. These
earlier techniques, where a single channel in a non-myocyte is probed,
can miss a potential drug interaction. A better approach is where a cell
expressingmany types of ion channels is used tomore accurately assess
all potential interactions. One group, using MEA, tested the effects of
eleven reference compounds on electrical activity of iPSC-CMs [89]. Of
these, 5 were hERG blockers, 2 were Ca2+ channel blockers, 1 was a
nonselective Ca2+ channel/hERG blocker, 1 was a KATP-channel blocker,
and 2were IKs blockers. The hERG blockers all prolonged the FPD, as ex-
pected, and the Ca2+ blockers shortened the FPD, as expected. The IKs
blockers had only minor effects on FPD, but there was no expected re-
sponse for either, and the authorswere able to use the iPSC-CMs to eval-
uate the potential role of these drugs aswell as the role of the IKs current
in cardiac myocyte function.
Furthermore, as mentioned above, iPSC-CMs can be useful models
for channelopathies, including Long QT syndrome, where the risk of a
fatal drug interaction is much higher than in a healthy individual.
Using cells from a LQTS-2 patient, effects of three compounds including
nifedipine, a Ca2+ channel blocker; pinacidil, a KATP-channel opener;
and ranolazine, a Na+ channel blocker were also examined [79]. Allthree drugs had predictable effects on LQTS iPSC-CMs, namely anti-
arrhythmic effects, demonstrating the ability of these cells to recapitu-
late the in vivo effects of anti-arrhythmic drugs in an in vitro system.
A second group, used another LQTS-2 iPSC line, and showed the ability
of an IKr blocker, E4031, to prolong APD/FPD, and of a KATP-channel
opener, nicorandil, to shorten APD and abolish EADs [53]. Furthermore,
they demonstrated counteracting effects of isoprenaline, a β-adrenergic
receptor agonist, and nadolol or propranolol, both β-adrenergic antago-
nists. On the other hand, the arrhythmogenic effects of the β antagonist
sotalolwere demonstrated at high concentrationswhen applied to LQTS
iPSC-CMs, but not control iPSC-CMs [80]. Moreover, other research
groups [82] have been able to show positive effects of dantrolene on ab-
errant Ca2+handling in cells from a patientwith CPVT. Taken together,
these studies in healthy aswell as diseased cells show that iPSC-CMs can
robustly examine the effects of current-affecting drugs on myocytes,
and may be able to predict effects in future studies. Additionally, as
shown above [89], iPSC-CMs can be useful for examining the mecha-
nism of action of untested compounds. In this context, there is a report
of altered hypertrophic signaling via the α-adrenergic pathway in
hiPSC-CMs that should be addressed by detailed further study when
pursuing iPSC lines for drug discovery [90].
18. Cell therapy
Pluripotent stem cells and derived cardiacmyocytes have long excit-
ed researchers with the prospect of being used as a clinical therapy. In
the ﬁeld of cardiology, there is great interest in using these cells as a po-
tential treatment for heart failure and post-infarction cardiomyopathy.
Pluripotent stem cell-derived cardiac myocytes injected directly into
the myocardium are an obvious starting point. If these cells can engraft
and electrically couple to existing myocardium they might provide suf-
ﬁcient contractile force to improve cardiac output. On the other hand,
the cells may not survive the procedure, or may fail to couple to native
myocytes, or may even be detrimental, as the procedure may cause
deadly arrhythmias. These potential complications warrant extensive
basic research before translation to human studies.
Several groups have published results from experiments injecting
stem cells into animal models. It was demonstrated that hESC-CMs
transplanted into immunocompromised NOD-SCID mice that had un-
dergonemyocardial infarction, engrafted and transiently improved car-
diac function [91]. Transplanted cells were tracked by GFP and anti-
human protein antibodies and the GFP+ cells were detected in the
heart at least 12weeks after transplant. The authors proposed function-
al coupling of transplanted and native cells based on connexin-43 and
desmoplakin staining. Four weeks after transplant, transplanted mice
had greater EF than non-transplanted controls; however, this difference
in EF was lost 12 weeks after transplant. At least two important caveats
to these results should be considered: ﬁrst, the population of
transplanted cells, taken from beating EBs, was only 20–25% CMs. Sec-
ond, connexin and desmoplakin staining are incomplete evidence of
functional coupling in the absence of electrical or ionic data, especially
since, as the authors noted, gap junctions and desmosomes were seen
between hESC-CMs and themselves, but not between hESC-CMs and
native myocytes. The same group later published results after injecting
3 times as many cells as previously, but noting, again, no functional im-
provement 12 weeks post-transplant [92].
In a similar study, EB-derived hESC-CMs were transplanted into
male Sprague–Dawley rats that had undergone LAD and were treated
with cyclosporine A and methylprednisolone to prevent rejection [93].
They reported evidence of engraftment of cells by imaging GFP or by
staining for human markers, noting engraftment took place mostly in
the border zone of the infarct region. Echocardiography showed de-
creased LV dilatation, greater fractional shortening (FS), and decreased
pulmonary congestion in animals transplanted with hESC-CMs.
In an effort to improve engraftment, human ES-CMs were
transplanted into infarcted rat hearts along with a “prosurvival cocktail
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pinacidil, IGF-1, and a caspase inhibitor ZVAD-fmk [94]. This group de-
tected engraftment based on human speciﬁc immunostaining and
qPCR. Based on echocardiography, hearts transplanted with hESC-CMs
showed decreased left ventricular end systolic diameter (LVESD) and
increased FS, as well as increased thickening of the left ventricular
wall in the infarct region. Later, they published a similar study [95],
this time injecting cells 1 month after infarction. This treatment im-
proved cardiac function, but did not alter dimensions or geometry of
the myocardium. In 2012, this group published a study [96] using
transplanted cells in immunosuppressed guinea pigs, wherein they
sought to demonstrate electrical coupling between hESC-CMs and
host myocytes using the genetically encoded calcium sensor GCaMP3.
To do this, they correlated ﬂuorescent transients to ECG to determine
synchrony. They also showed fewer arrhythmias in the form of prema-
ture ventricular contractions (PVCs) and ventricular tachycardia (VT) in
transplanted animals versus controls. However, in their isolated heart
studies, they demonstrated heterogeneous calcium transients and in-
complete coupling, as well as a loss of coupling at higher pacing fre-
quencies. In a technical tour de force, this group transplanted hESC-
CMs into a non-human primate model of infarction [97]. The hESC-CM
transplanted animals responded differently to treatment; while some
had improved EF after transplant, some had no improvement. Perhaps
most concerning, all hESC-CM transplanted animals displayed increased
arrhythmias following transplant. This important study represents the
current state of stem cell engraftment. It will be important to see
follow-up studies in coming years as the issues of stable, physiological
engraftment and functional restitution are established.
19. Concluding remarks
We have discussed a large number of characteristics of pluripotent
stem cell-derived cardiac myocytes, including differentiation methods,
gene and protein expression, functionality, as well as potential applica-
tions. We have drawn on the work of many outstanding and diverse re-
search groups to do so. Over the past decade our understanding of
pluripotency and cardiac development has expanded, and our ability
to engineer desired cell lineages continues to improve. Critical addition-
al study will allow us to improve and reﬁne differentiation protocols,
maturation protocols, and functionality assays. Our ability to model ge-
netic diseases, and, potentially, acquired diseases quickly and efﬁciently
will allow for a shift in methods of drug and therapy innovation. Finally,
continuedwork in the ﬁeldmay, someday, make iPSC-CM transplant an
effective and safe therapy for cardiovascular disease.
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